Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 27,977 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 27,977 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $92.36, for a total value of $2,583,955.72. Following the sale, the chief operating officer owned 10,294 shares of the company’s stock, valued at $950,753.84. This trade represents a 73.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ross Moat also recently made the following trade(s):

• On Friday, October 30th, Ross Moat sold 75,608 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $93.13, for a total value of $7,041,373.04.

Kiniksa Pharmaceuticals International Trading Up 2.7%

Shares of NASDAQ KNSA traded up $2.49 during mid-day trading on Tuesday, reaching $93.29. The company had a trading volume of 1,021,631 shares, compared to its average volume of 705,858. The stock has a market cap of $7.28 billion, a PE ratio of 71.76 and a beta of 0.04. The company has a 50-day moving average price of $79.39 and a two-hundred day moving average price of $60.29. Kiniksa Pharmaceuticals International, plc has a 1-year low of $37.02 and a 1-year high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The company had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. On average, research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current year.

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent analyst reports. Canaccord Genuity Group boosted their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. The Goldman Sachs Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently made changes to their positions in KNSA. Bank of America Corp DE lifted its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after purchasing an additional 506,576 shares in the last quarter. Rubric Capital Management LP boosted its holdings in shares of Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after purchasing an additional 421,347 shares during the period. Janus Henderson Group PLC grew its position in Kiniksa Pharmaceuticals International by 213.5% during the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock valued at $23,197,000 after purchasing an additional 327,595 shares in the last quarter. Spruce Street Capital LP grew its position in Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after purchasing an additional 326,081 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its position in Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after purchasing an additional 251,578 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.